HANX launches GLP-1 pharmacy as part of weight management programme

Pharmacist-prescribed GLP-1s will support patients who are also navigating menopause, PCOS and other health symptoms

UK-based sexual and intimate wellness brand HANX is adding GLP-1 prescriptions to its offering.

HANX will offer Mounjaro (tirzepatide) and Wegovy (semaglutide) through its digital pharmacy as part of a new weight management programme for women.

The new weight management programme will include pharmacist-prescribed GLP-1s, monthly deliveries in discreet packaging, clinic support and a 10-week meal and exercise plan.

GLP-1 medications work to decrease cravings, reduce blood sugar and delay gastric emptying to help patients feel fuller for longer. When combined with lifestyle changes outlined in this new weight management programme, patients can expect to lose up to 22.5%* of their body weight in a year.

HANX Co-Founder and Chief Product Officer, Dr Sarah Welsh, said:

“In the 10+ years I worked in NHS clinics, I heard from many patients about their struggles to manage weight, especially during menopause or when navigating conditions such as PCOS or endometriosis. In these cases, lifestyle changes alone aren’t always enough to support sustainable, successful weight loss.

“Maintaining a healthy weight is essential for our broader health and can reduce the risk of health problems such as heart disease and cancer. By offering our patients the option of safe, effective medication with educational resources, we’re aiming to truly support women on their weight management journey.”

Potential patients take a digital health consultation on the HANX platform, which is individually reviewed by a prescribing pharmacist. If deemed safe and suitable based on health information submitted, HANX customers will be eligible to join the Weight Management Programme.

HANX evolves

The introduction of GLP-1 medications is the latest step in HANX’s evolving vision to support women at every life stage.

Currently, HANX offers products through major UK retailers as a challenger brand in 2,000+ high street stores. It has also launched recently DTC in the US. HANX also provides products through its website and digital pharmacy including hormonal contraception, emergency contraceptive pills, supplements and treatments for thrush.

This new offering will form a key element of HANX’s evolution into the broader Femtech category to support women, especially those with conditions such as Polycystic Ovary Syndrome (PCOS), endometriosis and menopause.

Co-Founder and CEO, Farah Kabir, explains:

“We’ve spent the last seven years building trust and authority in the women’s health space, and have always been at the forefront with trusted and backable solutions, from prescription birth control to medical device grade products.

“I am delighted to be adding the latest groundbreaking, science-backed GLP-1 medication to our pharmacy repository. From fertility to libido to our menstrual cycles, weight has an impact on many core elements of women's health and it’s time we connect the dots. We’re proud to be the first women’s health brand to launch GLP-1 medications and believe strategically, it’s the natural next step for HANX. We can’t wait to offer our community these revolutionary tools to help them advocate for their health for the long term.”

GLP-1s in women’s health

There are growing signs that GLP-1 medication could be an increasingly important pillar within women’s health businesses. Earlier this year, virtual menopause clinic Stella (Vira Health) partnered with Habitual so that its patients can explore weight loss medication as part of menopause treatment. And in July, FutureFemHealth reported that ozempic and weight loss was one of eight key trends highlighted by VC-firm XRC Ventures as driving growth in the vitamins, minerals and supplements sector.

*Tirzepatide Once Weekly for the Treatment of Obesity, The New England Journal Of Medicine, 2022.